237 related articles for article (PubMed ID: 31180178)
1. AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.
Sieuwerts AM; Onstenk W; Kraan J; Beaufort CM; Van M; De Laere B; Dirix LY; Hamberg P; Beeker A; Meulenbeld HJ; Creemers GJ; van Weerden WM; Jenster GW; Nieuweboer AJM; Mathijssen RHJ; de Wit R; Martens JWM; Sleijfer S
Mol Oncol; 2019 Aug; 13(8):1795-1807. PubMed ID: 31180178
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Onstenk W; Sieuwerts AM; Kraan J; Van M; Nieuweboer AJ; Mathijssen RH; Hamberg P; Meulenbeld HJ; De Laere B; Dirix LY; van Soest RJ; Lolkema MP; Martens JW; van Weerden WM; Jenster GW; Foekens JA; de Wit R; Sleijfer S
Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
4. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
6. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
[TBL] [Abstract][Full Text] [Related]
7. Expression of AR-V7 and ARv
Tagawa ST; Antonarakis ES; Gjyrezi A; Galletti G; Kim S; Worroll D; Stewart J; Zaher A; Szatrowski TP; Ballman KV; Kita K; Tasaki S; Bai Y; Portella L; Kirby BJ; Saad F; Eisenberger MA; Nanus DM; Giannakakou P
Clin Cancer Res; 2019 Mar; 25(6):1880-1888. PubMed ID: 30301829
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
Gurioli G; Conteduca V; Brighi N; Scarpi E; Basso U; Fornarini G; Mosca A; Nicodemo M; Banna GL; Lolli C; Schepisi G; Ravaglia G; Bondi I; Ulivi P; De Giorgi U
BMC Med; 2022 Jan; 20(1):48. PubMed ID: 35101049
[TBL] [Abstract][Full Text] [Related]
9. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
10. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
[TBL] [Abstract][Full Text] [Related]
11. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
[TBL] [Abstract][Full Text] [Related]
12. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.
Ashizawa T; Nagata M; Nakamura S; Hirano H; Nagaya N; Lu Y; Horie S
Sci Rep; 2022 Oct; 12(1):18016. PubMed ID: 36289357
[TBL] [Abstract][Full Text] [Related]
14. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
15. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P
Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921
[TBL] [Abstract][Full Text] [Related]
17. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.
Isebia KT; Mostert B; Belderbos BPS; Buck SAJ; Helmijr JCA; Kraan J; Beaufort CM; Van MN; Oomen-de Hoop E; Sieuwerts AM; van IJcken WFJ; van den Hout-van Vroonhoven MCGN; Brouwer RWW; Oole E; Hamberg P; Haberkorn BCM; Helgason HH; de Wit R; Sleijfer S; Mathijssen RHJ; Martens JWM; Jansen MPHM; van Riet J; Lolkema MP
Eur J Cancer; 2022 Dec; 177():33-44. PubMed ID: 36323051
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Total, PTEN
Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
[TBL] [Abstract][Full Text] [Related]
20. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
